Immunovia AB (OTCPK:IMMVF)
$ 0.07382 0 (0%) Market Cap: 8.20 Mil Enterprise Value: 3.48 Mil PE Ratio: 0 PB Ratio: 2.76 GF Score: 49/100

Immunovia AB (publ) Corporate Call Transcript

Jul 12, 2023 / 01:00PM GMT
Release Date Price: $1.55
Operator

Ladies and gentlemen, welcome to the Immunovia Press Conference Call. I'm George, the Chorus Call cooperator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to Jeff Borcherding, CEO. Please go ahead, sir.

Jeff Borcherding;publ;Global CEO;President
Immunovia AB

()-&

Thank you very much, and good afternoon, everyone.

Yesterday, we announced a major plan to restructure our operations to focus on our promising next-generation test for the detection of pancreatic cancer. I am excited about the test we have in development and wanted to share additional information about this decision and our path forward.

As we discussed on the first quarter earnings call, we face 3 major challenges. The first is demanding payer requirements for robust clinical data. This clinical data is key to securing reimbursement from U.S. payers and generating revenue.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot